Highlights

  • enGene reports quarterly EPS of (USD 0.73), below consensus estimates
  • Institutional ownership remains above 64% following recent position changes
  • Analysts maintain mixed ratings with updated price targets

enGene (NASDAQ:ENGN) released its quarterly earnings results on Monday, reporting a net loss that exceeded market expectations. The company posted earnings per share (EPS) of (USD 0.73) for the quarter, compared with analysts’ consensus estimate of (USD 0.55), according to data cited by Zacks. The reported figure represented a miss of (USD 0.18).

The earnings update comes amid continued scrutiny of operating performance and cost structures, as the company remains in a loss-making phase. No additional financial guidance was disclosed alongside the earnings release.

Institutional Holdings Activity

Recent regulatory filings indicate several institutional investors and hedge funds adjusted their exposure to enGene during the year. Cresset Asset Management LLC initiated a new position in the second quarter, with holdings valued at approximately USD 36,000. Paloma Partners Management Co also opened a new position during the same period, valued at around USD 38,000.

Raymond James Financial Inc. expanded its position in the third quarter, increasing its stake by 383.6%. The firm now holds 10,000 shares, valued at about USD 68,000, after purchasing an additional 7,932 shares. Millennium Management LLC raised its holdings by 57.3% during the third quarter, bringing its total to 20,502 shares valued at roughly USD 140,000.

Citadel Advisors LLC also increased its position during the third quarter, lifting its stake by 153.3%. The firm now holds 58,370 shares of enGene, with a reported value of approximately USD 399,000. Overall, institutional investors and hedge funds account for about 64.16% of the company’s outstanding shares.

Analyst Ratings and Price Targets

Several research firms have updated their views on enGene in recent months. Morgan Stanley increased its price objective from USD 18.00 to USD 19.00 and assigned an “overweight” rating in a note dated November 12. Oppenheimer reiterated an “outperform” rating and raised its price target to USD 33.00 from USD 30.00.

Citigroup maintained a “market outperform” rating, while HC Wainwright reaffirmed a “buy” rating with a price target of USD 25.00. In contrast, Weiss Ratings reiterated a “sell (d-)” rating on the stock.

According to MarketBeat data, analyst coverage currently includes one Strong Buy rating, seven Buy ratings, one Hold rating, and one Sell rating. The stock carries an average rating of “Moderate Buy,” with a consensus price target of USD 22.38.

Shares of ENGN last traded at USD 8.77 on December 22, 2025.